share_log

Despite Delivering Investors Losses of 65% Over the Past 3 Years, STAAR Surgical (NASDAQ:STAA) Has Been Growing Its Earnings

Despite Delivering Investors Losses of 65% Over the Past 3 Years, STAAR Surgical (NASDAQ:STAA) Has Been Growing Its Earnings

儘管在過去3年中給投資者帶來了65%的損失,但STAAR Surgical(納斯達克股票代碼:STAA)的收益一直在增長
Simply Wall St ·  04/26 03:56

It is doubtless a positive to see that the STAAR Surgical Company (NASDAQ:STAA) share price has gained some 61% in the last three months. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 65% in the last three years. So the improvement may be a real relief to some. While many would remain nervous, there could be further gains if the business can put its best foot forward.

毫無疑問,STAAR外科公司(納斯達克股票代碼:STAA)的股價在過去三個月中上漲了約61%,這是一個積極因素。但是,對於三年來的驚人回報來說,這只是微不足道的回報。事實上,股價在過去三年中悲慘地下跌了65%。因此,這種改善可能使某些人鬆了一口氣。儘管許多人仍會感到緊張,但如果企業能夠盡力而爲,可能會有進一步的收益。

The recent uptick of 3.2% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近上漲3.2%可能是即將發生的事情的積極信號,因此讓我們來看一下歷史基本面。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。評估公司情緒變化的一種有缺陷但合理的方法是將每股收益(EPS)與股價進行比較。

Although the share price is down over three years, STAAR Surgical actually managed to grow EPS by 50% per year in that time. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.

儘管股價在三年內下跌,但在此期間,STAAR Surgical實際上設法將每股收益每年增長50%。鑑於股價的反應,人們可能會懷疑每股收益並不能很好地指導該期間的業務表現(可能是由於一次性的虧損或收益)。否則,該公司過去曾被過度炒作,因此其增長令人失望。

It's worth taking a look at other metrics, because the EPS growth doesn't seem to match with the falling share price.

值得一看其他指標,因爲每股收益的增長似乎與股價的下跌不符。

Revenue is actually up 21% over the three years, so the share price drop doesn't seem to hinge on revenue, either. It's probably worth investigating STAAR Surgical further; while we may be missing something on this analysis, there might also be an opportunity.

在過去的三年中,收入實際上增長了21%,因此股價下跌似乎也不取決於收入。可能值得進一步研究STAAR Surgical;雖然我們在分析中可能遺漏了一些東西,但也可能有機會。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。

earnings-and-revenue-growth
NasdaqGM:STAA Earnings and Revenue Growth April 25th 2024
納斯達克通用汽車公司:STAA 收益和收入增長 2024 年 4 月 25 日

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free report showing analyst forecasts should help you form a view on STAAR Surgical

我們認爲,內部人士在去年進行了大量收購,這是積極的。話雖如此,大多數人認爲收益和收入增長趨勢是更有意義的業務指南。這份顯示分析師預測的免費報告應該可以幫助您對STAAR Surgical形成看法

A Different Perspective

不同的視角

STAAR Surgical shareholders are down 29% for the year, but the market itself is up 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 8%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for STAAR Surgical you should know about.

STAAR Surgical的股東今年下跌了29%,但市場本身上漲了27%。但是,請記住,即使是最好的股票有時也會在十二個月內表現不如市場。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺8%。最近的拋售可能是一個機會,因此可能值得查看基本面數據以尋找長期增長趨勢的跡象。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,考慮風險。每家公司都有它們,我們發現了一個你應該知道的STAAR Surgical警告信號。

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

還有很多其他公司有內部人士購買股票。你可能不想錯過這份業內人士正在收購的成長型公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論